Try our Advanced Search for more refined results
Health
-
March 03, 2026
States Can't Duck Regeneron Counterclaims In FCA Case
Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity grounds, a Massachusetts federal judge has ruled.
-
March 03, 2026
4th Circ. Won't Revive Retired Miners' Health Fight
The Fourth Circuit refused Tuesday to reopen a dispute over lifetime retirement health and life insurance benefits from a proposed class of retired coal miners, keeping in place a West Virginia federal court's judgment that broadly favored the company following a seven-day bench trial.
-
March 03, 2026
Curaleaf Says No Private Info Leaked In Buyers' Data Suit
Curaleaf Inc. is asking a Florida federal court to throw out a suit alleging that its website failed to protect buyers' personal and health information, saying none of the information the site or its software collects is personal property or healthcare information.
-
March 03, 2026
Judge Won't Rely On DOJ 'Decency' In Trans Records Case
A Pennsylvania federal judge blocked the U.S. Department of Justice from getting patient-specific records of gender-affirming care at the University of Pittsburgh Medical Center Children's Hospital, excoriating the government's request and its reasoning for demanding the data.
-
March 03, 2026
1st Circ. Won't Revive Boston's Opioid Claims Against PBMs
Boston lost its bid to revive opioid crisis-related claims against two pharmacy benefit managers, as a First Circuit panel affirmed that the suit came years too late.
-
March 03, 2026
FTC Makes 'Significant Progress' In OptumRx, Caremark Talks
Federal Trade Commission staffers got more time Tuesday for settlement talks with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, with staffers citing considerable progress in the weeks since inking a deal with Express Scripts.
-
March 03, 2026
Fla. Billing Co. To Settle With Feds Over $15M Medicare Fraud
The U.S. government has settled its False Claims Act lawsuit with a medical coding and billing business it accused of aiding a Miami-based laboratory in fraudulently billing Medicare for more than $15 million in genetic tests.
-
March 02, 2026
High Court Blocks California's Gender Privacy Rule
The U.S. Supreme Court on Monday reinstated a lower court order that barred California public schools from allowing transgender and gender-nonconforming students to use different names and pronouns at school without their parents' knowledge or consent while the order is appealed.
-
March 02, 2026
E-Rate Could Cut Some Regulatory Fat, FCC Told
While the Federal Communications Commission is looking for regulations to get rid of, one organization said it has a list of options for the agency to consider when it comes to the E-Rate subsidy program.
-
March 02, 2026
Texas AG Says Gender Care Ban Includes Mental Health
Mental-health professionals in Texas risk losing their licenses and public funding if they "facilitate" the gender-affirming care banned under state law, said an opinion issued Friday by Attorney General Ken Paxton, which calls them the "gatekeepers."
-
March 02, 2026
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial
An Illinois federal judge on Monday permanently tossed a lawsuit accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, saying the plaintiffs can't plausibly show that their legally protected information ever left Abbott's website.
-
March 02, 2026
Epic Must Face Price Conspiracy Claims Over Gallstone Drug
Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.
-
March 02, 2026
3rd Circ. Unsure Criticism Of Prof's DEI Stance Is Defamation
A Third Circuit panel on Monday questioned whether the retraction of a former University of Pittsburgh program director's article criticizing diversity, equity and inclusion was a purely academic debate the courts should avoid, or if statements that it "misrepresented" facts were enough to sustain defamation claims.
-
March 02, 2026
SEC Inks $200K Settlement In False PPE Press Release Suit
The CEO and consultant of a consumer goods company will pay over $200,000 to settle the U.S. Securities and Exchange Commission's claims that they artificially inflated the company's share price by nearly 200% by disseminating a false press release at the beginning of the COVID-19 pandemic.
-
March 02, 2026
Anthem Avoids Patients' Ghost Network Suit In NY
A New York federal judge on Monday granted Anthem escape from a proposed class action from patients who alleged inaccuracies in the insurer's mental health provider directory violated New York state laws, holding their claims were preempted by federal employee health benefits law.
-
March 02, 2026
NC Care Co. Operator Urges Judge To Ax Wage Verdict
A North Carolina residential mental health company and its owner have urged a federal judge to nix a jury verdict finding that they underpaid workers, saying the employees relied on speculative evidence and a damages summary that was disclosed too late.
-
March 02, 2026
6th Circ. Upholds 12-Year Stint For Mich. Doc In 'Pill Mill' Case
The Sixth Circuit affirmed the convictions and 12-year prison sentence of a Michigan doctor accused of operating a cash-only "pill mill" that wrote thousands of opioid prescriptions, holding that the trial judge properly handled the jury instructions and key evidentiary rulings.
-
March 02, 2026
Hagens Berman Denied Rehearing Bid In Sanctions Dispute
The Third Circuit on Monday rejected plaintiffs firm Hagens Berman Sobol Shapiro LLP's request to reconsider weighing in on the sanctions dispute in a since-dropped product liability case that resulted in the trial court judge referring the firm for possible criminal investigation.
-
March 02, 2026
Gyre, Cullgen Merge In $300M All-Stock Deal
Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in an all-stock deal valued at roughly $300 million.
-
March 02, 2026
Physical Therapy Practice Owners Get 6 Years For Fraud
The owners of a defunct Erie, Pennsylvania, physical therapy practice were each sentenced to six years in prison for defrauding federal healthcare programs by overbilling, prosecutors announced Monday.
-
March 02, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket last week featured headline-grabbing disputes involving fast food giant Jack in the Box and boxing legend Mike Tyson's cannabis venture, alongside high-stakes fights over merger documents, appraisal rights and a $75 million renewable energy funding clash.
-
March 02, 2026
Drugmakers Warn Justices Oregon Pricing Law Risks Secrets
Pharmaceutical manufacturers have asked the U.S. Supreme Court to overturn Oregon's drug‑pricing transparency law, arguing it forces companies to publicly justify their pricing decisions and give up valuable trade secrets in violation of the First Amendment and the Constitution's takings clause.
-
March 02, 2026
Pepsi Extinguishes Employee's Tobacco Fee Lawsuit
Pepsi has defeated a proposed class action claiming it unlawfully charged employees who used tobacco more to obtain health insurance, with a New York federal judge shutting down a worker's argument that the company hadn't given tobacco users a sufficient way to avoid the surcharge.
-
February 27, 2026
Recovery Provider Asks For Halt To Anthem's Claims Practices
A Colorado mental health and substance use treatment facilities operator and its patients asked a Colorado federal judge to stop Anthem Blue Cross and Blue Shield's claims practices, alleging its process violates federal benefits and mental health parity laws and disrupts access to lifesaving care.
-
February 27, 2026
Do H-1B Fee Waivers Exist In Practice? Attys Have Doubts
More than five months after President Donald Trump rolled out a $100,000 fee for some H-1B petitions, immigration attorneys say the administration hasn't adjudicated fee exemption requests, leaving them uncertain about whether the waiver is merely notional.
Expert Analysis
-
Shutdown Imperils Telehealth Access For Medicare Patients
The federal government shutdown that commenced on Oct. 1 coincided with the expiration of certain telehealth flexibilities that had preserved expansive access to telehealth services for Medicare beneficiaries following COVID-19, creating significant legal and financial uncertainty for healthcare providers and patients, say attorneys at Robinson & Cole.
-
Mass. Ruling May Pave New Avenue To Target Subpoenas
A Massachusetts federal court’s recent decision to quash a subpoena seeking information on gender-affirming care at Boston Children’s Hospital is a significant departure from courts' deferential approach to subpoena enforcement, and may open a new pathway for practitioners challenging investigative tools in the future, say attorneys at Gibson Dunn.
-
What To Expect After FDA Warnings To GLP-1 Compounders
The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.
-
Why Justices Seem Inclined To Curtail Del. Affidavit Statute
After recent oral argument before the U.S. Supreme Court in Berk v. Choy — asking whether Delaware's affidavit-of-merit statute applies in federal diversity actions, or whether the Federal Rules of Civil Procedure displace the state requirement — it appears the court is poised to simplify the standard approach, says Eric Weitz of The Weitz Law Firm.
-
How Financial Cos. Can Prep As NYDFS Cyber Changes Loom
Financial institutions supervised by the New York State Department of Financial Services can prepare for two critical cybersecurity requirements relating to multifactor authentication and asset inventories, effective Nov. 1, by conducting gap analyses and allocating resources to high-risk assets, among other steps, say attorneys at Pillsbury.
-
Series
Adapting To Private Practice: 3 Tips On Finding The Right Job
After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.
-
How Courts May Interpret Data-Driven Healthcare Fraud Suits
As the U.S. Department of Justice and other agencies increasingly turn to data mining as an enforcement tool, courts will have to determine how far data alone can take a fraud case, and sound theory, clinical expertise and institutional context will play an important role, say Jaime Jones at Sidley and Andrée-Anne Fournier and Atang Gilika at Analysis Group.
-
AG Watch: Va. Race Spotlights Consumer Protection Priorities
Ahead of the state's attorney general election, Virginia companies should assess how either candidate's approach could affect their compliance posture, with incumbent Jason Miyares promising a business-friendly atmosphere that prioritizes public safety and challenger Jay Jones pledging to focus on economic justice and corporate accountability, says Chuck Slemp at Cozen O’Connor.
-
Series
Painting Makes Me A Better Lawyer
Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.
-
Hybrid Claims In Antitrust Disputes Spark Coverage Battles
Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.
-
Drug Ad Crackdown Demonstrates Admin's Aggressive Stance
Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.
-
Protecting Sensitive Court Filings After Recent Cyber Breach
In the wake of a recent cyberattack on federal courts' Case Management/Electronic Case Files system, civil litigants should consider seeking enhanced protections for sensitive materials filed under seal to mitigate the risk of unauthorized exposure, say attorneys at Redgrave.
-
How Gov't Shutdown Will Affect Federal Health Agencies
Federal health agencies' contingency plans indicate that many major programs will remain insulated from disruption during the ongoing government shutdown, but significant policy proposals will likely be delayed and the Trump administration's emphasis on reduction-in-force plans distinguishes this shutdown from past lapses, says Miranda Franco at Holland & Knight.
-
Series
Judging Figure Skating Makes Me A Better Lawyer
Judging figure skating competitions helps me hone the focus, decisiveness and ability to process complex real-time information I need in court, but more importantly, it makes me reengage with a community and my identity outside of law, which, paradoxically, always brings me back to work feeling restored, says Megan Raymond at Groombridge Wu.
-
$100K H-1B Fee May Disrupt Rural Healthcare Needs
The Trump administration's newly imposed $100,000 supplemental fee on new H-1B petitions may disproportionately affect healthcare employers' ability to recruit international medical graduates, and the fee's national interest exceptions will not adequately solve ensuing problems for healthcare employers or medically underserved areas, say attorneys at Holland & Knight.